+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

An open, randomized assessment of the efficacy and safety of two transdermal estradiol patches for relief of climacteric symptoms



An open, randomized assessment of the efficacy and safety of two transdermal estradiol patches for relief of climacteric symptoms



Maturitas 27(Suppl. ): 209




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 030039219

Download citation: RISBibTeXText


Related references

Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study. Arzneimittel-Forschung 50(3): 293-300, 2000

Transdermal 17 beta estradiol patches for the control of climacteric symptoms. International Journal of Gynecology & Obstetrics (ABSTR Suppl.): 385, 1991

Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies. Arzneimittel-Forschung 49(11): 933-943, 1999

Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 7(2): 189-196, 2004

Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 9(3): 195-207, 2002

Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecological Endocrinology 20(1): 30-35, 2005

Efficacy and tolerability of transdermal 17 beta-estradiol in patients with climacteric symptoms: Dose titration according to individual choice. Current Therapeutic Research 57(7): 506-515, 1996

Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clinical Therapeutics 31(3): 503-513, 2009

Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group. International Journal of Fertility and Menopausal Studies 40(3): 126-134, 1995

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Current Medical Research and Opinion 27(7): 1375-1383, 2011

Comparison of transdermal and subcutaneous administration of estradiol in the treatment of climacteric symptoms. Nederlands Tijdschrift Voor Geneeskunde 131(50): 2301-2304, 1987

Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 13(2): 222-231, 2006

Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine 9(2): 85-92, 2002

Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis. Menopause 23(3): 294-303, 2016

Efficacy and safety of human placenta extract in alleviating climacteric symptoms: prospective, randomized, double-blind, placebo-controlled trial. Journal of Obstetrics and Gynaecology Research 35(6): 1096-1101, 2009